rs12678719

This validation study confirms the association of ZFPM2 intronic SNP rs12678719 with antipsychotic-induced parkinsonism (AIP) in schizophrenia patients (p=0.009, OR=1.93 in whole sample; p=0.002, OR=2.85 in African Americans). The AIP-risk G allele was also associated with lower dopaminergic neuron binding in the putamen of early Parkinson's disease patients (p=0.026), suggesting ZFPM2 may affect nigrostriatal pathway integrity.

A pharmacogenomic GWAS of 397 schizophrenia patients from the CATIE trial identified genetic variants associated with antipsychotic-induced parkinsonism (AIP) severity. The most significant SNP was rs12476047 (P=3.13×10⁻⁶, OR=3.21) near FIGN; candidate genes included EBF1 (rs891903, P=4.06×10⁻⁵), NOVA1 (rs8006700, rs1950420), and RAPGEF5 (rs7804311). Although no SNPs reached genome-wide significance threshold (P<4.2×10⁻⁷), the study identified promising genetic candidates for AIP susceptibility.